Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics (NQ: SGMO )

0.5116 -0.0093 (-1.79%)
Streaming Delayed Price Updated: 9:33 AM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 25,727
Open 0.5105
Bid (Size) 0.5025 (9)
Ask (Size) 0.5116 (2)
Prev. Close 0.5209
Today's Range 0.5022 - 0.5230
52wk Range 0.2911 - 1.780
Shares Outstanding 145,337,046
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga

Performance

YTD
-8.04%
-8.04%
1 Month
-20.27%
-20.27%
3 Month
+12.64%
+12.64%
6 Month
+5.35%
+5.35%
1 Year
-68.99%
-68.99%

More News

Read More
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
From Sangamo Therapeutics, Inc.
Via Business Wire
4 Analysts Assess Sangamo Therapeutics: What You Need To Know
Via Benzinga
Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Where Sangamo Therapeutics Stands With Analysts
Via Benzinga
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Via Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
From Sangamo Therapeutics, Inc.
Via Business Wire
What 8 Analyst Ratings Have To Say About Sangamo Therapeutics
Via Benzinga
Earnings Scheduled For March 13, 2024
Via Benzinga
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
From Sangamo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
2 low-priced gene therapy stocks to speculate on
Via MarketBeat
Exposures Product Safety
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
What To Know About RBC Capital's Downgrade of Sangamo Therapeutics
Via Benzinga
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Earnings Scheduled For November 1, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.